Skip to main content
OpenTrials
Completed

NCT Number: NCT00461123

Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy

The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of hemoglobin in the respective tissue. Therefore, increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of the laser application and consequently shortening of the required duration of laser application.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostatic Hypertrophy, Benign Genital Diseases Genital Diseases, Male Male Urogenital Diseases Prostatic Diseases Prostatic Hyperplasia Urogenital Diseases

Age range

18 year–80 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Heidelberg, Baden-Wurttemberg, 69112, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men with benign prostate hypertrophy requiring surgical treatment
  • Age up to 80 years
  • Documented, dated, written Informed Consent
  • Anesthesiologists agreement with swallowing 1 tablet one hour prior surgery

Exclusion criteria

  • Any unstable medical, psychiatric, or substance abuse disorder
  • History of previous prostatectomy
  • Patients suspect of prostate cancer
  • Hereditary degenerative retinal disorder
  • History of previous Non-arteric Anterior Ischemic Optic Neuropathy (NAION) episode or unilateral vision impairment
  • Any cardiovascular condition
  • History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
  • Uncontrolled atrial fibrillation/flutter at screening
  • Severe chronic or acute liver disease
  • Chronic hematological disease which may lead to priapism
  • Bleeding disorder
  • Significant active peptic ulceration
  • Resting hypotension
  • History of positive test for Hepatitis B surface antigen or Hepatitis C
  • Symptomatic postural hypotension within 6 months of Visit 1
  • Patients who subjectively or in the opinion of the investigator did not tolerate the initial dose of study medication well
  • Subjects who are taking nitrates or nitric oxide donors
  • Subjects who are taking androgens or anti-androgens
  • Subjects who are taking potent inhibitors of cytochrome P4503A4
  • Subjects who have received any investigational drug within 30 days of Visit 1
  • Using of alpha-blockers during two days prior to first dosing of study medication and after ablation of prostate
  • Use of inhibitors of 5-alpha reductase after ablation of prostate
  • Subjects with serum creatinine clearance <30.0 mL/min
  • Elevation of Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >3 times the upper limit of normal
  • Subjects with known hypersensitivity to Vardenafil
  • Subjects who are illiterate or unable to understand subject diaries
  • Subjects who would be non-compliant with the study visit schedule

Treatment and study plan

Vardenafil (Levitra, BAY38-9456)

Drug

One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.

Placebo

Drug

One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.

Primary outcomes

  1. Baseline-adjusted Least Squared (LS) Means of Peak Urinary Flow (Qmax) at 3 Months After Surgery or Last Observation Carried Forward (LOCF)

    Time frame: baseline and up to 3 months after surgery

    Baseline (pre-surgery Day -1) adjusted least squares (LS)-means at 3 months after surgery (Day +90, last observation carried forward (LOCF)) in peak urinary flow.

Secondary outcomes

  1. Baseline-adjusted Least Squared (LS) Means of International Prostate Symptom Score (IPSS) Total Score at 3 Months After Surgery or Last Observation Carried Forward (LOCF)

    Time frame: baseline and up to 3 months after surgery

    Baseline (pre-surgery Day -1) adjusted LS-means at 3 months after surgery (Day +90, LOCF) in IPSS total score. IPSS is a questionnaire on benign prostate hyperplasia, including seven 6-point items on symptoms and one 7-point item on quality of life. Total score: sum of items 1 through 7; minimum: 0 (best); maximum: 41 (worst).

  2. Baseline-adjusted Least Squared (LS) Means of Post-void Residual (PVR) Volume at 3 Months After Surgery or Last Observation Carried Forward (LOCF)

    Time frame: baseline and up to 3 months after surgery

    Baseline (pre-surgery Day -1) adjusted LS-means at 3 months after surgery (Day +90, last observation carried forward (LOCF)) in PVR volume. PVR is the amount of urine left in the bladder after a person has passed urine.

  3. Baseline-adjusted Least Squared (LS) Means of the Number of Urinary Incontinence Episodes Per Week at 3 Months After Surgery or Last Observation Carried Forward (LOCF)

    Time frame: baseline and up to 3 months after surgery

    Baseline (pre-surgery Day -1) adjusted LS-means at 3 months after surgery (Day +90, last observation carried forward (LOCF)) in the number of incontinence episodes. Urinary incontinence is an involuntary excretion (passing) of urine. Urinary incontinence episodes were collected in the patient diary.

  4. Duration of Surgery

    Time frame: on the day of surgery, without any further allowable time window

    Duration of prostate laser ablation, i.e. Greenlight(TM) laser surgery.

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Randomized, Double-blind, Parallel Group Prospective Pilot Study to Assess the Effect of Vardenafil on Clinical Outcome and on Procedure Duration After Green Light Laser-ablation of the Prostate Gland for Therapy of Benign Prostate Hypertrophy (BPH)

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Apr 17, 2007
Registry last updated
Dec 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.